These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27793034)

  • 1. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
    Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
    Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
    Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F
    Oncotarget; 2016 Dec; 7(51):84675-84687. PubMed ID: 27835869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
    Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
    Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
    Kim D; Koh Y; Yoon SS
    Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
    Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
    Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
    Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F
    Clin Cancer Res; 2015 Apr; 21(7):1628-38. PubMed ID: 25623213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
    Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
    Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126.
    Ito M; Zhao N; Zeng Z; Chang CC; Zu Y
    Cancer Gene Ther; 2010 Sep; 17(9):633-44. PubMed ID: 20448669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.
    Liu C; Iqbal J; Teruya-Feldstein J; Shen Y; Dabrowska MJ; Dybkaer K; Lim MS; Piva R; Barreca A; Pellegrino E; Spaccarotella E; Lachel CM; Kucuk C; Jiang CS; Hu X; Bhagavathi S; Greiner TC; Weisenburger DD; Aoun P; Perkins SL; McKeithan TW; Inghirami G; Chan WC
    Blood; 2013 Sep; 122(12):2083-92. PubMed ID: 23801630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
    Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
    Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
    Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
    Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
    Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.
    Xu W; Kim JW; Jung WJ; Koh Y; Yoon SS
    Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.